|View printer-friendly version|
|Michael Amoroso to Join Kite as Senior Vice President and Head of Worldwide Commercial, Cell Therapy|
-- Mr. Amoroso Brings Significant Expertise in Oncology to New Role --
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005263/en/
Mr. Amoroso joins Kite from
“Michael brings to the Kite organization significant expertise in the
area of oncology and in the commercialization of cancer products,”
commented Dr. Milligan. “This experience will help us as we seek to
build on our existing portfolio, expand our commercial presence in cell
This press release includes forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995 that are
subject to risks, uncertainties and other factors. These risks,
uncertainties and other factors could cause actual results to differ
materially from those referred to in the forward-looking statements. The
reader is cautioned not to rely on these forward-looking statements.
These and other risks are described in detail in Gilead’s Quarterly
Report on Form 10-Q for the quarter ended
For more information on Kite, please visit the company’s website at www.kitepharma.com. Learn more about Gilead at www.gilead.com, follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.
Gilead Sciences, Inc.
Minimum 20 minute delay